Rationale for MEK/BRAF Combinations in Melanoma
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses the rationale for combining agents like dabrafenib with trametinib or binimetinib with encorafenib for patients with melanoma.<br />
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses the rationale for combining agents like dabrafenib (Tafinlar) with trametinib (Mekinist) or binimetinib (Mektovi) with encorafenib (Braftovi) for patients with melanoma.
We’ve known for a number of years that mutatedBRAFis a bonafide therapeutic target for this patient population, Flaherty explains. Approximately 45% of patients with melanoma have activating mutations in BRAF. Around 2009, vemurafenib (Zelboraf) and dabrafenib came along and proved thatBRAFmutations were therapeutic targets. Within a few years, these drugs were FDA-approved for this patient population.
Response Time and BRAF Status Factor Into IO Selection for Melanoma
January 29th 2025During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 affect their choice of therapy for metastatic melanoma in the first article of a 2-part series.
Read More
